MedTrace Logo

PRIDE III Prison Interventions and HIV Prevention Collaboration

NCT06962033 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-05-11

No results posted yet for this study

Summary

The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).

Conditions

  • Hiv
  • Opioid Use

Interventions

BEHAVIORAL

Opioid Agonist Therapy

Opioid Agonist Therapy (OAT) as HIV prevention

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Frederick L Altice, MD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-05
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States
  • Georgia
  • Kyrgyzstan
  • Moldova
  • Tajikistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06962033 on ClinicalTrials.gov